Age, gender, and percentage of circulating osteoprogenitor (COP) cells: The COP Study
dc.contributor.author | Gunawardene, Piumali | |
dc.contributor.author | Al Saedi, Ahmed | |
dc.contributor.author | Singh, Lakshman | |
dc.contributor.author | Bermeo, Sandra | |
dc.contributor.author | Vogrin, Sara | |
dc.contributor.author | Phu, Steven | |
dc.contributor.author | Suriyaarachchi, Pushpa | |
dc.contributor.author | Pignolo, Robert J. | |
dc.contributor.author | Duque, Gustavo | |
dc.date.accessioned | 2018-04-02T21:04:00Z | |
dc.date.available | 2018-04-02T21:04:00Z | |
dc.date.issued | 2017-06 | |
dc.description.abstract | Circulating osteoprogenitor (COP) cells are blood-borne cellswhich express a variety of osteoblasticmarkers and are able to formbone nodules in vivo.Whereas a high percentage of COP cells (%COP) is associatedwith vascular calcification, low %COP has been associated with disability and frailty. However, the reference range of %COP in age- and gender-matching populations, and the age-related changes in %COP remain unknown. A cross-sectional studywas undertaken in 144 healthy volunteers inWestern Sydney (20–90 year-old, 10male and 10 female subjects per decade). %COP was quantified by flow cytometry. A high inter-and intra-rater reliability was found. In average, in this healthy population average of %COP was 0.42. There was no significant difference in %COP among the age groups. Similarly, no significant difference was found in %COP with gender, weight, height or BMI. In addition, we identified a normal reference range of %COP of 0.1–3.8%. In conclusion, in addition to the identification of steady levels of COP cells with age, we also identified a normal reference range of %COP, which could be used in future studies looking at musculoskeletal diseases in older populations. | eng |
dc.identifier.issn | 05315565 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12442/1933 | |
dc.language.iso | eng | eng |
dc.publisher | Elsevier | eng |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
dc.rights.license | licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional | spa |
dc.source | Experimental Gerontology | spa |
dc.source | Vol. 96 (2017) | spa |
dc.source.uri | https://doi.org/10.1016/j.exger.2017.06.004 | spa |
dc.subject | Osteosarcopenia | eng |
dc.subject | Stem cells | eng |
dc.subject | Musculoskeletal | eng |
dc.subject | Circulating osteoprogenitors | eng |
dc.title | Age, gender, and percentage of circulating osteoprogenitor (COP) cells: The COP Study | eng |
dc.type | article | eng |
dcterms.references | Almeida, M., 2012. Aging mechanisms in bone. BoneKEy Rep. 1. | eng |
dcterms.references | Beane, O.S., Fonseca, V.C., Cooper, L.L., Koren, G., Darling, E.M., 2014. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One 9, e115963 | eng |
dcterms.references | Benisch, P., Schilling, T., Klein-Hitpass, L., Frey, S.P., Seefried, L., Raaijmakers, N., et al., 2012. The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One 7, e45142. | eng |
dcterms.references | Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373–383. | eng |
dcterms.references | Cherian, S., Moore, J., Bantly, A., et al., 2005. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin. Cytom. 64, 9. | eng |
dcterms.references | Demontiero, O., Boersma, D., Suriyaarachchi, P., Duque, G., 2014. Clinical outcomes of impaired muscle and bone interactions. Clin. Rev. Bone Miner. Metab. 12, 86–92. | eng |
dcterms.references | Egan, K.P., Kim, J.H., Mohler 3rd, E.R., Pignolo, R.J., 2011. Role for circulating osteogenic precursor cells in aortic valvular disease. Arterioscler. Thromb. Vasc. Biol. 31, 2965–2971. | eng |
dcterms.references | Eghbali-Fatourechi, G.Z., Lamsam, J., Fraser, D., Nagel, D., Riggs, B.L., Khosla, S., 2005. Circulating osteoblast-lineage cells in humans. N. Engl. J. Med. 352, 1959–1966. | eng |
dcterms.references | Grounds, M.D., 2014. Therapies for sarcopenia and regeneration of old skeletal muscles: more a case of old tissue architecture than old stem cells. BioArchitecture 4, 81–87 | eng |
dcterms.references | Gunawardene, P., Bermeo, S., Vidal, C., Al-Saedi, A., Chung, P., Boersma, D., et al., 2016. Association between circulating osteogenic progenitor cells and disability and frailty in older persons: the Nepean osteoporosis and frailty study. J. Gerontol. A Biol. Sci.Med. Sci. 71, 1124–1130. | eng |
dcterms.references | Ishihara, A., Bertone, A.L., 2012. Cell-mediated and direct gene therapy for bone regeneration. Expert. Opin. Biol. Ther. 12, 411–423. | eng |
dcterms.references | Jiang, S.S., Chen, C.H., Tseng, K.Y., Tsai, F.Y., Wang, M.J., Chang, I.S., et al., 2011. Gene expression profiling suggests a pathological role of human bone marrow-derived mesenchymal stem cells in aging-related skeletal diseases. Aging 3, 672–684. | eng |
dcterms.references | Magni, P., Dozio, E., Galliera, E., Ruscica, M., Corsi, M.M., 2010. Molecular aspects of adipokine–bone interactions. Curr. Mol. Med. 10, 522–532. | eng |
dcterms.references | Pignolo, R.J., Kassem, M., 2011. Circulating osteogenic cells: implications for injury, repair, and regeneration. J. Bone Miner. Res. 26, 1685–1693. | eng |
dcterms.references | Pirro,M., Leli, C., Fabbriciani, G.,Manfredelli, M.R., Callarelli, L., Bagaglia, F., et al., 2010. Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. Osteoporos. Int. 21, 297–306. | eng |
dcterms.references | Sethe, S., Scutt, A., Stolzing, A., 2006. Aging ofmesenchymal stem cells. Ageing Res. Rev. 5, 91–116. | eng |
dcterms.references | Stolzing, A., Jones, E., McGonagle, D., Scutt, A., 2008. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech. Ageing Dev. 129, 163–173. | eng |
dcterms.references | Suda, R.K., Billings, P.C., Egan, K.P., Kim, J.H., McCarrick-Walmsley, R., Glaser, D.L., et al., 2009. Circulating osteogenic precursor cells in heterotopic bone formation. Stem Cells 27, 2209–2219. | eng |
dcterms.references | Tong, J., Li,W., Vidal, C., Yeo, L.S., Fatkin, D., Duque, G., 2011. Lamin A/C deficiency is associated with fat infiltration of muscle and bone. Mech. Ageing Dev. 132, 552–559. | eng |
dcterms.references | Toupadakis, C.A., Granick, J.L., Sagy,M.,Wong, A., Ghassemi, E., Chung, D.J., Borjesson, D.L., Yellowley, C.E., 2013. Mobilization of endogenous stem cell populations enhances fracture healing in a murine femoral fracture model. Cytotherapy 15, 1136–1147. | eng |
dcterms.references | Urbich, C., Dimmeler, S., 2004. Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95, 343–353. | eng |
dcterms.references | Zhou, S., Greenberger, J.S., Epperly, M.W., Goff, J.P., Adler, C., Leboff, M.S., Glowacki, J., 2008. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 7, 335–343. | eng |
Archivos
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 368 B
- Formato:
- Item-specific license agreed upon to submission
- Descripción: